全文获取类型
收费全文 | 472846篇 |
免费 | 61220篇 |
国内免费 | 25532篇 |
专业分类
耳鼻咽喉 | 8070篇 |
儿科学 | 8866篇 |
妇产科学 | 7374篇 |
基础医学 | 43321篇 |
口腔科学 | 7088篇 |
临床医学 | 71505篇 |
内科学 | 95583篇 |
皮肤病学 | 10414篇 |
神经病学 | 32851篇 |
特种医学 | 18270篇 |
外国民族医学 | 214篇 |
外科学 | 73237篇 |
综合类 | 51607篇 |
现状与发展 | 149篇 |
一般理论 | 22篇 |
预防医学 | 26623篇 |
眼科学 | 12932篇 |
药学 | 34250篇 |
344篇 | |
中国医学 | 17907篇 |
肿瘤学 | 38971篇 |
出版年
2024年 | 1334篇 |
2023年 | 8840篇 |
2022年 | 12521篇 |
2021年 | 19354篇 |
2020年 | 17830篇 |
2019年 | 13002篇 |
2018年 | 18637篇 |
2017年 | 17132篇 |
2016年 | 17595篇 |
2015年 | 22658篇 |
2014年 | 33166篇 |
2013年 | 30863篇 |
2012年 | 28503篇 |
2011年 | 31559篇 |
2010年 | 26340篇 |
2009年 | 26463篇 |
2008年 | 23078篇 |
2007年 | 21326篇 |
2006年 | 23739篇 |
2005年 | 20778篇 |
2004年 | 13892篇 |
2003年 | 12031篇 |
2002年 | 10755篇 |
2001年 | 11522篇 |
2000年 | 11441篇 |
1999年 | 12310篇 |
1998年 | 9136篇 |
1997年 | 8981篇 |
1996年 | 7734篇 |
1995年 | 7171篇 |
1994年 | 5189篇 |
1993年 | 3699篇 |
1992年 | 4231篇 |
1991年 | 3862篇 |
1990年 | 3199篇 |
1989年 | 3062篇 |
1988年 | 2591篇 |
1987年 | 2177篇 |
1986年 | 1996篇 |
1985年 | 1633篇 |
1984年 | 1077篇 |
1983年 | 898篇 |
1982年 | 760篇 |
1981年 | 640篇 |
1980年 | 551篇 |
1979年 | 531篇 |
1978年 | 415篇 |
1977年 | 487篇 |
1975年 | 346篇 |
1972年 | 382篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
“三全育人”视角下思政教育机制实践与探索——“杏林成长导师”计划的构建 《医学教育管理》2021,7(6):656-660
“三全育人”是高校思政教育工作的关键一环,也是中医药高校推动思政教育的重要内容。以“三全育人”为视角对北京中医药大学思想政治教育举措“杏林成长导师”计划路径、内容深入分析,运用统计分析和文献研究方法,剖析该计划对中医学专业大学生的学业、思想和实践等多个层面的现实成效,从而为“三全育人”理念在中医药院校制度建构中的应用提供新的视角与方法。 相似文献
22.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
23.
24.
25.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
26.
Weina Cheng Yazhi Wang Jingxian Liu Xiaofei Li Ming Yu Cancan Duan Liu Liu Jianyong Zhang 《Journal of applied toxicology : JAT》2022,42(6):970-980
Cantharidin (CTD) is an effective antitumor agent. However, it exhibits significant hepatotoxicity, the mechanism of which remains unclear. In this study, biochemical and histopathological analyses complemented with ultra-high-performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS)-based targeted metabolomic analysis of bile acids (BAs) were employed to investigate CTD-induced hepatotoxicity in rats. Sixteen male and female Sprague–Dawley rats were randomly divided into two groups: control and CTD (1.0 mg/kg) groups. Serum and liver samples were collected after 28 days of intervention. Biochemical, histopathological, and BA metabolomic analyses were performed for all samples. Further, the key biomarkers of CTD-induced hepatotoxicity were identified via multivariate and metabolic pathway analyses. In addition, metabolite–gene–enzyme network and Kyoto Encyclopedia of Genes and Genomes pathway analyses were used to identify the signaling pathways related to CTD-induced hepatotoxicity. The results revealed significantly increased levels of biochemical indices (alanine aminotransferase, aspartate aminotransferase, and total bile acid). Histopathological analysis revealed that the hepatocytes were damaged. Further, 20 endogenous BAs were quantitated via UHPLC-MS/MS, and multivariate and metabolic pathway analyses of BAs revealed that hyocholic acid, cholic acid, and chenodeoxycholic acid were the key biomarkers of CTD-induced hepatotoxicity. Meanwhile, primary and secondary BA biosynthesis and taurine and hypotaurine metabolism were found to be associated with the mechanism by which CTD induced hepatotoxicity in rats. This study provides useful insights for research on the mechanism of CTD-induced hepatotoxicity. 相似文献
27.
Feng Song Li Ruipiao Wang Zhiying 《Odontology / the Society of the Nippon Dental University》2022,110(3):508-522
Odontology - To investigate the characterization and function of a novel porous osteogenic material (PLLA / DDM) containing polylactic acid and demineralized dentin matrix. The surface morphology... 相似文献
28.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
29.
30.